Chart Events
Performance Outlook
| Previous Close | 34.20 |
| Open | 34.29 |
| Bid | 34.47 x 1200 |
| Ask | 34.43 x 3200 |
| Day's Range | 33.96 - 34.55 |
| 52 Week Range | 26.45 - 43.08 |
| Volume | 30,561,785 |
| Avg. Volume | 39,909,840 |
| Market Cap | 191.815B |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | 20.15 |
| EPS (TTM) | 1.71 |
| Earnings Date | Apr 26, 2021 - Apr 30, 2021 |
| Forward Dividend & Yield | 1.56 (4.54%) |
| Ex-Dividend Date | Jan 28, 2021 |
| 1y Target Est | 41.09 |
Fair Value
Related Research
- Reuters
NHS England invites people aged 56 to 59 to book COVID-19 vaccinations in coming week
NHS England has invited people aged 56 to 59 to book COVID-19 vaccinations in the coming week, with letters to 850,000 people in that age bracket landing on doorsteps from Saturday and another 850,000 due to land Monday. "The latest invites have been sent after more than eight in 10 people aged 65 to 69 took up the offer of a jab", the National Health Service said in an emailed statement on Sunday. "NHS staff have vaccinated more than 18 million people across England, meaning more than one third of the adult population have already received the life-saving jab."
- Reuters
Chile donates 20,000 doses of Sinovac coronavirus vaccine to Ecuador
Ecuador has received a donation of some 20,000 doses of the Sinovac coronavirus vaccine from Chile, Ecuador's President Lenin Moreno said on Saturday, in a sign of the stark disparities in South American countries' inoculation campaigns. Chile, one of Latin America's wealthiest countries, ranks sixth in the world for per-capita vaccine shots administered, according to Reuters data, with a quarter of the population now having received a dose.
- Motley Fool
How Worried Should Investors Be About the South African Coronavirus Variant?
The B1351 coronavirus variant from South Africa poses a threat to the currently authorized vaccines from Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX)/Pfizer (NYSE: PFE) because they weren't specifically designed to protect against that variant. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the ins and outs of the vaccines' potential to protect against the variants and what the companies are doing to deal with the new challenge. Brian Orelli: We got some data last week published in the New England Journal of Medicine on the coronavirus vaccines protecting against the South African variant -- that's the B1351 -- by Pfizer and BioNTech vaccine, the neutralization was weaker by about two-thirds.
